Core Viewpoint - Becton Dickinson's Chief Financial Officer Chris DelOrefice will leave the company on December 5 to pursue a new professional opportunity [1] Company Summary - The departure of the CFO may impact the company's financial strategy and operations moving forward [1]

[BD Announces CFO Transition Plan and Preliminary Fiscal 2025 Results](index=1&type=section&id=BD%20Announces%20CFO%20Transition%20Plan%20and%20Preliminary%20Fiscal%202025%20Results) BD announced a CFO transition and strong preliminary fiscal 2025 results, including revenue growth and EPS outlook [CFO Transition Announcement](index=1&type=section&id=CFO%20Transition%20Announcement) BD announced CFO Chris DelOrefice's departure, appointing Vitor Roque as interim CFO effective December 5, 2025 - Chris DelOrefice, Executive Vice President and CFO, will depart BD effective **December 5, 2025**[2](index=2&type=chunk) - Vitor Roque, Senior Vice President of Finance, has been named interim CFO[2](index=2&type=chunk) - CEO Tom Polen acknowledged DelOrefice's contributions to the BD 2025 strategy and highlighted Roque's extensive experience within the company[3](index=3&type=chunk) [Preliminary Fiscal 2025 Financial Results](index=1&type=section&id=Preliminary%20Fiscal%202025%20Financial%20Results) BD reported strong preliminary Q4 and full year fiscal 2025 revenue, expecting adjusted diluted EPS at or above guidance midpoint [Fourth Quarter Fiscal 2025 Preliminary Revenue](index=1&type=section&id=Fourth%20Quarter%20Fiscal%202025%20Preliminary%20Revenue) BD reported preliminary Q4 fiscal 2025 revenue of approximately **$5.9 billion**, with strong reported, currency-neutral, and organic growth Fourth Quarter Fiscal 2025 Preliminary Revenue Metrics | Metric | Value | | :--- | :--- | | Preliminary Unaudited Revenue | ~$5.9 billion | | Reported Increase | ~8.3% | | Currency-Neutral Increase | ~7.0% | | Organic Increase | ~3.9% | - Strong growth was observed in the BD Interventional segment, Advanced Patient Monitoring, and Medication Delivery Solutions, despite a greater than anticipated impact from a dynamic macro environment on Pharmaceutical Systems vaccines and Biosciences academic and government research[4](index=4&type=chunk) [Full Year Fiscal 2025 Preliminary Revenue](index=1&type=section&id=Full%20Year%20Fiscal%202025%20Preliminary%20Revenue) BD's preliminary full year fiscal 2025 revenue reached approximately **$21.8 billion**, with robust reported, adjusted currency-neutral, and organic growth Full Year Fiscal 2025 Preliminary Revenue Metrics | Metric | Value | | :--- | :--- | | Preliminary Unaudited Revenue | ~$21.8 billion | | Reported Increase | ~8.2% | | Adjusted Currency-Neutral Increase | ~7.7% | | Organic Increase | ~2.9% | [Full Year Fiscal 2025 Adjusted Diluted EPS Outlook](index=2&type=section&id=Full%20Year%20Fiscal%202025%20Adjusted%20Diluted%20EPS%20Outlook) BD expects full year fiscal 2025 **adjusted diluted EPS at or above the midpoint** of its guidance, excluding non-GAAP adjustments - BD expects to deliver full year fiscal 2025 **adjusted diluted EPS at or above the midpoint** of its previously issued guidance[6](index=6&type=chunk) - The adjusted diluted EPS outlook excludes potential charges or gains such as non-cash amortization of intangible assets, acquisition-related charges, separation-related costs, and certain tax matters[7](index=7&type=chunk) [Conference Call and Presentation Materials](index=2&type=section&id=Conference%20Call%20and%20Presentation%20Materials) BD will host an audio webcast on **November 6, 2025**, for Q4 and full year fiscal 2025 results, with materials on its investor relations website - An audio webcast for Q4 and full year fiscal 2025 results will be held on **Thursday, November 6, 2025, at 8 a.m. (ET)**[8](index=8&type=chunk) - The webcast and related materials will be accessible via BD's investor relations website at www.bd.com/investors[8](index=8&type=chunk) [Non-GAAP Financial Measures and Preliminary Information Disclaimers](index=2&type=section&id=Non-GAAP%20Financial%20Measures%20and%20Preliminary%20Information%20Disclaimers) This section clarifies BD's non-GAAP financial measures and disclaims the preliminary, unaudited nature of presented financial results [Explanation of Non-GAAP Financial Measures](index=2&type=section&id=Explanation%20of%20Non-GAAP%20Financial%20Measures) BD uses non-GAAP financial measures (currency-neutral, adjusted, organic revenue growth) for clearer operational performance, excluding distorting items - Non-GAAP financial measures (currency-neutral, adjusted, and organic revenue growth) are used to help investors understand year-over-year performance, underlying trends, and future prospects[9](index=9&type=chunk) - Adjusted revenues for full year fiscal 2024 exclude accruals related to the Italian government medical device pay back legislation and another legal matter, primarily from prior years[10](index=10&type=chunk) - Organic Revenue growth is defined as foreign currency-neutral revenues further adjusted for the impact of acquisitions and divestitures during the first 12 months post-transaction[12](index=12&type=chunk) [Preliminary Financial Information Disclaimer](index=4&type=section&id=Preliminary%20Financial%20Information%20Disclaimer) The financial information is preliminary, unaudited, and subject to change, with actual results potentially differing materially - The financial information as of September 30, 2025, is **preliminary, unaudited, and subject to change**[14](index=14&type=chunk) - Actual results may differ materially due to the completion of financial closing procedures, audit procedures, and final adjustments[14](index=14&type=chunk) - These preliminary estimates are not a comprehensive statement of financial results and should not be viewed as a substitute for full GAAP financial statements[14](index=14&type=chunk) [About BD](index=4&type=section&id=About%20BD) BD is a leading global medical technology company with **over 70,000 employees**, advancing health through innovative solutions and partnerships - BD is one of the largest global medical technology companies, with **over 70,000 employees**[15](index=15&type=chunk) - The company's mission is to advance the world of health by improving medical discovery, diagnostics, and the delivery of care[15](index=15&type=chunk) - BD develops innovative technology, services, and solutions to enhance clinical therapy, clinical processes, disease detection, and research capabilities[15](index=15&type=chunk) [Forward-Looking Statements and Risk Factors](index=4&type=section&id=Forward-Looking%20Statements%20and%20Risk%20Factors) This section highlights forward-looking statements, subject to business risks and uncertainties from macroeconomic conditions, international markets, and regulatory changes - The press release contains forward-looking statements based on current expectations and assumptions, involving business risks and uncertainties[16](index=16&type=chunk) - Factors that could cause actual results to vary materially include macroeconomic conditions, international market conditions (e.g., geopolitical developments), competitive factors, product efficacy/safety concerns, and changes to legislation or regulations impacting healthcare systems[16](index=16&type=chunk)[17](index=17&type=chunk) - Other risks include supply chain disruptions, labor constraints, inflationary pressures, currency rate fluctuations, increased interest rates, cybersecurity threats, and uncertainties of litigation or investigations[16](index=16&type=chunk)[17](index=17&type=chunk) [Preliminary Supplemental Revenue Information Tables](index=7&type=section&id=Preliminary%20Supplemental%20Revenue%20Information%20Tables) This section provides preliminary reconciliations of BD's reported revenue to organic and adjusted revenue for Q4 and full year fiscal 2025 [Q4 Fiscal 2025 Preliminary Revenue Reconciliation](index=7&type=section&id=Q4%20Fiscal%202025%20Preliminary%20Revenue%20Reconciliation) This table reconciles preliminary Q4 fiscal 2025 reported revenue to organic revenue, detailing FX impact and inorganic adjustments Q4 Fiscal 2025 Preliminary Revenue Reconciliation (Millions of USD) | Metric | 2025 (A) (Millions of USD) | 2024 (B) (Millions of USD) | FX Impact (C) (Millions of USD) | % Change Reported (D) | % Change FXN (E) | | :--- | :--- | :--- | :--- | :--- | :--- | | TOTAL REVENUES | $5,890 | $5,437 | $75 | 8.3% | 7.0% | | Less: Inorganic revenue adjustment | 170 | — | 3 | NM | NM | | Organic Revenue | $5,720 | $5,437 | $72 | 5.2% | 3.9% | - The inorganic revenue adjustment accounts for incremental revenue from acquisitions and revenue decline from divestitures within the first 12 months post-transaction, including Advanced Patient Monitoring[20](index=20&type=chunk) [Full Year Fiscal 2025 Preliminary Revenue Reconciliation](index=8&type=section&id=Full%20Year%20Fiscal%202025%20Preliminary%20Revenue%20Reconciliation) This table reconciles preliminary full year fiscal 2025 reported revenue to adjusted and organic revenue, including legislative and inorganic adjustments Full Year Fiscal 2025 Preliminary Revenue Reconciliation (Millions of USD) | Metric | 2025 (A) (Millions of USD) | 2024 (B) (Millions of USD) | FX Impact (C) (Millions of USD) | % Change Reported (D) | % Change FXN (E) | | :--- | :--- | :--- | :--- | :--- | :--- | | TOTAL REVENUES | $21,840 | $20,178 | $30 | 8.2% | 8.1% | | Add: Reduction for government (1) legislative and legal matters | — | 67 | — | (100.0%) | (100.0%) | | Adjusted Total Revenues | $21,840 | $20,245 | $30 | 7.9% | 7.7% | | Less: Inorganic revenue adjustment (2) | 977 | — | 1 | NM | NM | | Organic Revenue | $20,863 | $20,245 | $29 | 3.1% | 2.9% | - The reduction for government legislative and legal matters in 2024 primarily relates to accruals for the Italian government medical device pay back legislation and another legal matter from years prior to fiscal year 2024[23](index=23&type=chunk) - The inorganic revenue adjustment includes incremental revenue attributable to acquisitions, such as Advanced Patient Monitoring in the Medical Segment[23](index=23&type=chunk)

Core Insights - BD (Becton, Dickinson and Company) announced a transition plan for its CFO Chris DelOrefice, who will leave the company on December 5, 2025, with Vitor Roque appointed as interim CFO [1][2] - The company provided preliminary revenue results for the fourth quarter and full year of fiscal 2025, indicating strong growth despite challenges in certain segments [2][3] Transition of Leadership - Chris DelOrefice has been a key member of the Executive Leadership Team for four years, contributing to the BD 2025 strategy and portfolio transformation [2] - Vitor Roque, with two decades of experience at BD, will take over as interim CFO, ensuring a smooth transition [1][2] Preliminary Revenue Results - Fourth quarter preliminary revenue is approximately $5.9 billion, reflecting an estimated increase of 8.3% on a reported basis, 7.0% on a currency-neutral basis, and 3.9% on an organic basis [3][8] - Full year preliminary revenue is approximately $21.8 billion, representing an estimated increase of 8.2% on a reported basis, 7.7% on a currency-neutral basis, and 2.9% on an organic basis [3][8] Strategic Outlook - The company continues to navigate a dynamic macro environment, with strong growth in segments like BD Interventional, Advanced Patient Monitoring, and Medication Delivery Solutions [2] - BD plans to share more on its New BD strategy and expectations for fiscal 2026 in an upcoming earnings call [2] Financial Performance Metrics - The expected adjusted diluted earnings per share (EPS) for fiscal 2025 is projected to be at or above the midpoint of previously issued guidance [2] - The company emphasizes the use of non-GAAP financial measures to provide better insight into underlying operational performance [4][5]

Core Insights - Becton, Dickinson and Company (BDX) has initiated the XTRACT Registry to evaluate the Rotarex Catheter System for treating peripheral artery disease (PAD) lesions, marking a significant step for the company in enhancing its Peripheral Intervention (PI) business unit [1][3][10] Company Developments - The XTRACT Registry aims to enroll up to 600 patients across the U.S., with follow-up evaluations at 30 days, six months, and 12 months to assess the safety and effectiveness of the Rotarex Catheter System in real-world settings [3] - The Rotarex Catheter System is designed for dual functionality, serving as both an atherectomy and thrombectomy device, which is expected to improve treatment outcomes for PAD lesions [2][10] - BD's management anticipates that the first patient enrollment will generate robust real-world evidence to support the effectiveness of the Rotarex Catheter System, ultimately enhancing patient outcomes and advancing PAD care [7][10] Market Context - PAD currently affects over 21 million Americans and more than 200 million people globally, with untreated cases leading to serious cardiovascular complications and lower limb amputations [6] - The global PAD market is projected to grow from $7.3 billion in 2024 to $11.3 billion by 2033, at a compound annual growth rate (CAGR) of 5.2%, driven by rising disease prevalence and technological advancements [8] Financial Performance - BD has a market capitalization of $53.47 billion and an earnings yield of 7.9%, which is higher than the industry average of 6.6% [5] - In the last reported quarter, BD achieved an earnings surprise of 7.6%, indicating strong performance in its PI business unit, particularly in Peripheral Vascular Disease [5][11] Stock Performance - Following the announcement of the XTRACT Registry, BD's shares declined by nearly 3.8%, despite the potential long-term benefits of the new initiative for top-line growth [4] - Over the past year, BD's stock has decreased by 21.8%, contrasting with a 1.4% rise in the industry and a 13.9% gain in the S&P 500 [12]

Core Insights - Becton, Dickinson and Co. (BDX) is a multinational medical technology company focused on manufacturing and selling medical devices, instruments, and reagents globally [1] Financial Performance - The company is set to report its Q4 2025 earnings on November 6, with analysts expecting an EPS of $3.92, an increase from $3.81 in the prior year [2] - Quarterly revenue is anticipated to reach $5.92 billion, up from $5.44 billion a year earlier [2] - In Q3 2025, Becton Dickinson reported an adjusted EPS of $3.68, exceeding the consensus estimate of $3.41, and revenues of $5.51 billion, slightly above the consensus of $5.49 billion [3] Growth and Strategic Initiatives - The CEO highlighted an increase in organic growth trajectory in Q3, along with strong margin and EPS growth, which led to a raised EPS guidance for the full year [4] - The full-year 2025 adjusted EPS guidance has been raised to a range of $14.30 to $14.45, reflecting a $0.18 increase and a 9.4% growth at the midpoint [4] - An agreement was announced to combine BD's Biosciences and Diagnostic Solutions business with Waters Corporation, aimed at creating a leader in life sciences and diagnostics focused on high-volume testing [4]

Core Insights - Becton, Dickinson and Company (BDX) has announced a multi-year collaboration with Opentrons Labworks to integrate robotic liquid-handling capabilities into its single-cell multiomics instruments, aiming to automate critical experimental steps for disease research and drug development [1][5][8] - This partnership is expected to enhance BD's Biosciences (BDB) business unit and strengthen its position in the niche market of lab automation [2][8] - Despite the potential benefits of the collaboration, BDX's stock experienced a decline of nearly 1.8% following the announcement [3] Company Performance - BD currently has a market capitalization of $54.19 billion and an earnings yield of 7.8%, which is higher than the industry average of 6.4% [4] - In the last reported quarter, BDX achieved an earnings surprise of 7.6% [4] - Over the past year, BD's shares have decreased by 19.8%, contrasting with a 2.7% rise in the industry and a 17.8% gain in the S&P 500 [10] Partnership Details - The collaboration aims to integrate the BD Rhapsody System with the Opentrons Flex platform, allowing for hands-free workflows in single-cell multiomics experiments [5][6] - An automation-compatible module for the BD Rhapsody System is expected to automate next-generation sequencing library preparation and cell capture [5][6] Industry Prospects - The global sequencing market is projected to grow from $15.54 billion in 2023 to $62.48 billion by 2030, at a CAGR of 22.2%, driven by increasing demand for gene therapy and consumer genomics [7] - The partnership with Opentrons is anticipated to significantly boost BD's business in light of the favorable market conditions [7]

9k+ Digital Media Outlets 270k+ Journalists Opted In Media: Investors: Fallon McLoughlin Adam Reiffe Director, Public Relations Vice President, Investor Relations 201.258.0361 201.847.6927        [email protected] [email protected]     SOURCE BD (Becton, Dickinson and Company) WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers , /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD ...

Core Insights - BD has enrolled the first patient in the XTRACT™ Registry, a study aimed at evaluating the real-world performance of the Rotarex™ Catheter System for treating peripheral artery disease (PAD) [1][2][4] Company Overview - BD is a leading global medical technology company focused on improving medical discovery, diagnostics, and care delivery [6] - The company employs over 70,000 individuals and operates in nearly every country, addressing significant global health challenges [6] XTRACT™ Registry Details - The XTRACT™ Registry is a prospective, multi-center, single-arm study designed to collect data on the Rotarex™ Catheter System's effectiveness in treating PAD [1][2] - The registry aims to enroll up to 600 patients across 100 clinical sites in the U.S., with follow-up evaluations at 30 days, six months, and 12 months post-procedure [3][4] Rotarex™ Catheter System Features - The Rotarex™ Catheter System utilizes three mechanisms of action to effectively remove plaque and thrombus, functioning as both an atherectomy and thrombectomy device [4] - The device is designed to enhance patient outcomes by modifying and detaching mixed morphology lesions while actively aspirating material away [4] Market Context - PAD affects over 21 million Americans and more than 200 million people globally, with untreated cases leading to serious cardiovascular complications [5]

, /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Opentrons Labworks, Inc., recognized worldwide for accessible lab automation with more than 10,000 robotic systems deployed, today announced a multi-year collaboration. Together, BD and Opentrons will integrate robotic liquid-handling capabilities into BD single-cell multiomics instruments, automating critical experimental steps to accelerate and scale disease research and drug development. BD ...

Accessibility StatementSkip Navigation SUMTER, S.C., Oct. 3, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today will commemorate 55 years of manufacturing excellence at its Sumter, South Carolina facility, which throughout its history has been a core site within the Company's extensive U.S. manufacturing footprint. Continue Reading BD Celebrates 55 Years of Manufacturing Excellence and Impact in Sumter, S.C. About BD Vacutainer productsBD ...